O
OPTR

OrbiMed’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

OrbiMed’s Portfolio OPTR Stock Details OPTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-536,000
Closed -$7.76M – 150
2013
Q2 		$7.76M Buy
+536,000
New +$7.81M 0.16% 86

Other funds holding OPTR

WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

OrbiMed's OPTR Position: Q3 2013 in Review

OrbiMed sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q3 2013, closing a stake of 536,000 shares — an estimated $7.76M sold.

OrbiMed first reported a position in OPTR in Q2 2013 and held it in 1 quarter. The position peaked at $7.76M in Q2 2013. 104 funds tracked by Wall St. Rank hold OPTR as of Q3 2013.

  • OrbiMed reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q3 2013 after selling out during the quarter.
  • OrbiMed sold 536,000 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q3 2013, an estimated $7.76M.
  • OrbiMed first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 1 quarter.
  • OrbiMed's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $7.76M in Q2 2013.
  • 104 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q3 2013.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.